BACKGROUND: New psoriasis therapies have increased the ability to achieve skin clearance. However, insufficient evidence exists on the impact of total skin clearance from the patient perspective. OBJECTIVE: We sought to determine if complete skin clearance is clinically meaningful compared with treatment responses without clearance. METHODS: Pooled data from 3 phase-III trials were used to compare results for patients with complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 or static Physician Global Assessment score 0) with patients without complete skin clearance (PASI 75 to <100 or static Physician Global Assessment score 1) based on Psoriasis Symptom Inventory and Dermatology Life Quality Index. RESULTS: Percentages of patients with Psoriasis Symptom Inventory score 0 were 45% for those achieving PASI 100 and 8% for PASI 75 to <100 (P < .001). Respective percentages with Dermatology Life Quality Index score 0/1 were 80% and 55% (P < .001). PASI 100 resulted in incremental improvement over PASI 90 to <100 (incremental differences of 28% for Psoriasis Symptom Inventory score 0 and 18% for Dermatology Life Quality Index score 0). Similar results were observed for static Physician Global Assessment scores 0 versus 1. CONCLUSIONS: Complete skin clearance represents a clinically meaningful end point and outcome for patients, reflected in experiences of no psoriasis symptoms and no impairment on health-related quality of life.
BACKGROUND: New psoriasis therapies have increased the ability to achieve skin clearance. However, insufficient evidence exists on the impact of total skin clearance from the patient perspective. OBJECTIVE: We sought to determine if complete skin clearance is clinically meaningful compared with treatment responses without clearance. METHODS: Pooled data from 3 phase-III trials were used to compare results for patients with complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 or static Physician Global Assessment score 0) with patients without complete skin clearance (PASI 75 to <100 or static Physician Global Assessment score 1) based on Psoriasis Symptom Inventory and Dermatology Life Quality Index. RESULTS: Percentages of patients with Psoriasis Symptom Inventory score 0 were 45% for those achieving PASI 100 and 8% for PASI 75 to <100 (P < .001). Respective percentages with Dermatology Life Quality Index score 0/1 were 80% and 55% (P < .001). PASI 100 resulted in incremental improvement over PASI 90 to <100 (incremental differences of 28% for Psoriasis Symptom Inventory score 0 and 18% for Dermatology Life Quality Index score 0). Similar results were observed for static Physician Global Assessment scores 0 versus 1. CONCLUSIONS: Complete skin clearance represents a clinically meaningful end point and outcome for patients, reflected in experiences of no psoriasis symptoms and no impairment on health-related quality of life.
Keywords:
Dermatology Life Quality Index; Psoriasis Area and Severity Index; Psoriasis Symptom Inventory; health-related quality of life; patient-reported outcomes; plaque psoriasis; static Physician Global Assessment
Authors: Lluís Puig; Mark Lomaga; Kristin Hollister; Yves Dutronc; Lovisa Berggren; Peter C M van de Kerkhof Journal: Acta Derm Venereol Date: 2020-12-09 Impact factor: 3.875
Authors: Nikolai Loft; Alexander Egeberg; Mads Kirchheiner Rasmussen; Lars Erik Bryld; Christoffer V Nissen; Tomas Norman Dam; Kawa Khaled Ajgeiy; Lars Iversen; Lone Skov Journal: Acta Derm Venereol Date: 2021-01-04 Impact factor: 3.875
Authors: J F Merola; P-D Ghislain; J N Dauendorffer; A Potts Bleakman; A J M Brnabic; R Burge; E Riedl Journal: J Eur Acad Dermatol Venereol Date: 2020-02-05 Impact factor: 6.166
Authors: Paolo Gisondi; Marina Talamonti; Andrea Chiricozzi; Stefano Piaserico; Paolo Amerio; Anna Balato; Federico Bardazzi; Piergiacomo Calzavara Pinton; Anna Campanati; Angelo Cattaneo; Paolo Dapavo; Clara De Simone; Valentina Dini; Maria C Fargnoli; Maria L Flori; Marco Galluzzo; Claudio Guarneri; Claudia Lasagni; Francesco Loconsole; Ada Lo Schiavo; Piergiorgio Malagoli; Giovanna Malara; Santo R Mercuri; Maria L Musumeci; Luigi Naldi; Manuela Papini; Aurora Parodi; Concetta Potenza; Francesca Prignano; Franco Rongioletti; Luca Stingeni; Rossana Tiberio; Marina Venturini; Luca Bianchi; Antonio Costanzo; Francesco Cusano; Giampiero Girolomoni; Anna M Offidani; Ketty Peris Journal: Dermatol Ther (Heidelb) Date: 2021-01-11
Authors: A Blauvelt; K Papp; A Gottlieb; A Jarell; K Reich; C Maari; K B Gordon; L K Ferris; R G Langley; Y Tada; R G Lima; H Elmaraghy; G Gallo; L Renda; S Y Park; R Burge; J Bagel Journal: Br J Dermatol Date: 2020-01-15 Impact factor: 9.302
Authors: Jean-Philippe Lacour; Anthony Bewley; Edward Hammond; Jes B Hansen; Laura Horne; Carle Paul; Kristian Reich; Julien Seneschal; Clara De Simone; Anne Sohrt; Matthias Augustin; Giovanni Pellacani Journal: Dermatol Ther (Heidelb) Date: 2020-08-06